Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines

The epidermal growth factor receptor (EGFR, HER1) is a therapeutic target in head and neck squamous cell carcinoma (HNSCC). After initial promising results with EGFR‐targeted therapies such as cetuximab, therapeutic resistance has become a major clinical problem, and new treatment options are theref...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Oncol
Päätekijät: De Pauw, Ines, Lardon, Filip, Van den Bossche, Jolien, Baysal, Hasan, Fransen, Erik, Deschoolmeester, Vanessa, Pauwels, Patrick, Peeters, Marc, Vermorken, Jan Baptist, Wouters, An
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2018
Aiheet:
Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983215/
https://ncbi.nlm.nih.gov/pubmed/29603584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12197
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia